Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Dermatology ; 238(1): 170-179, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-33827090

RESUMO

BACKGROUND: Auricular keloids belong to the most perplexing medical conditions, which have significant psychosocial impact on the patient's body image and quality of life. SUMMARY: The article is purposed to provide dermatologists and plastic surgeons with the best proven practice using intralesional cryosurgery for the treatment of the different auricular keloid types in order to obtain superior clinical results by minimizing the probability of recurrence. In the past 20 years, the authors have developed novel procedures in order to increase the effectiveness of intralesional cryosurgery on auricular keloids, including hydrodissection, warm gauze technique, and excision of dangling skin. Long-lasting clinical results with a low recurrence rate and a satisfactory aesthetic outcome are achieved with no deformation of the ear framework.


Assuntos
Criocirurgia/normas , Pavilhão Auricular/cirurgia , Injeções Intralesionais/normas , Queloide/cirurgia , Guias de Prática Clínica como Assunto , Criocirurgia/métodos , Humanos , Injeções Intralesionais/métodos , Resultado do Tratamento
2.
Am J Clin Dermatol ; 21(6): 855-880, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32651806

RESUMO

Botulinum toxin type A (BoNTA) is a powerful neurotoxin that inhibits acetylcholine release from presynaptic vesicles. The potency and safety profile of BoNTA grant the toxin vast therapeutic potential. It has been used off-label for a variety of dermatologic conditions. This review aims to analyze published literature regarding the benefits and risks of the off-label use of BoNTA beyond facial lines, including eccrine hidrocystomas, enlarged pores, keloids and hypertrophic scars, hidradenitis suppurativa, hyperhidrosis, masseter muscle hypertrophy, and salivary gland hypertrophy, among others. A MEDLINE search from January 2000 to December 2019 was conducted on the off-label uses of botulinum toxin in dermatology.


Assuntos
Inibidores da Liberação da Acetilcolina/administração & dosagem , Toxinas Botulínicas Tipo A/administração & dosagem , Dermatologia/métodos , Uso Off-Label , Inibidores da Liberação da Acetilcolina/efeitos adversos , Toxinas Botulínicas Tipo A/efeitos adversos , Cicatriz Hipertrófica/tratamento farmacológico , Dermatologia/normas , Hidradenite Supurativa/tratamento farmacológico , Hidrocistoma/tratamento farmacológico , Humanos , Hiperidrose/tratamento farmacológico , Hipertrofia/tratamento farmacológico , Injeções Intralesionais/métodos , Injeções Intralesionais/normas , Injeções Subcutâneas/métodos , Injeções Subcutâneas/normas , Queloide/tratamento farmacológico , Músculo Masseter/anormalidades , Ensaios Clínicos Controlados Aleatórios como Assunto , Glândulas Salivares/patologia , Neoplasias das Glândulas Sudoríparas/tratamento farmacológico , Resultado do Tratamento
4.
AAPS PharmSciTech ; 19(8): 3829-3838, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30280351

RESUMO

To reduce the toxic and side effects of intravenous chemotherapeutic drugs on the tumor-patients, the aims of this study were to design and study intratumor-administrated irinotecan-loaded PLGA microspheres (CPT-11-PLGA-MS) in vitro and in vivo according to the structure characteristics of CPT-11. PLGA microspheres containing irinotecan were prepared by emulsion solvent evaporation method and evaluated in terms of their morphology, particle size analysis, in vitro drug release, drug retention and leakage studies in vivo, and pharmacodynamics studies. The CPT-11-PLGA-MS were spherical with mean size of 9.29 ± 0.02 µm, and average encapsulation efficiency were measured of 77.97 ± 1.26% along with the average drug loading of 7.08 ± 0.11%. DSC results indicated that the drug existed in the phase of uncrystallization in the microspheres. The formulation of CPT-11-PLGA-MS could prolong the in vitro drug release to 16 days following Weibull equation. In CPT-11-PLGA-MS after intratumor injection administration was significantly improved. The results demonstrated that the slow-sustained release of CPT-11-PLGA-MS in tumor tissue after intratumor injection of microspheres can reduce the drug leakage to the circulation system, maintain the drug retention, and improve the therapeutic effect, which could become a promising drug delivery system for CPT-11 and could maintain the most effective concentration at the target site to maximum limit.


Assuntos
Sistemas de Liberação de Medicamentos/métodos , Injeções Intralesionais/métodos , Irinotecano/administração & dosagem , Microesferas , Carga Tumoral/efeitos dos fármacos , Animais , Linhagem Celular Tumoral , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/química , Sistemas de Liberação de Medicamentos/normas , Avaliação Pré-Clínica de Medicamentos/métodos , Avaliação Pré-Clínica de Medicamentos/normas , Liberação Controlada de Fármacos , Feminino , Humanos , Injeções Intralesionais/normas , Irinotecano/química , Camundongos , Tamanho da Partícula , Distribuição Aleatória , Inibidores da Topoisomerase I/administração & dosagem , Inibidores da Topoisomerase I/química , Carga Tumoral/fisiologia
5.
Rev Soc Bras Med Trop ; 49(6): 774-776, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-28001228

RESUMO

INTRODUCTION:: Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS: Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals. RESULTS: The technique is described in detail sufficient to enable replication. CONCLUSIONS:: The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.


Assuntos
Antiprotozoários/administração & dosagem , Leishmaniose Cutânea/tratamento farmacológico , Meglumina/administração & dosagem , Compostos Organometálicos/administração & dosagem , Humanos , Injeções Intralesionais/normas , Antimoniato de Meglumina
6.
Rev. Soc. Bras. Med. Trop ; 49(6): 774-776, Dec. 2016. graf
Artigo em Inglês | LILACS | ID: biblio-1041383

RESUMO

Abstract INTRODUCTION: Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals. RESULTS The technique is described in detail sufficient to enable replication. CONCLUSIONS: The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.


Assuntos
Humanos , Compostos Organometálicos/administração & dosagem , Leishmaniose Cutânea/tratamento farmacológico , Meglumina/administração & dosagem , Antiprotozoários/administração & dosagem , Injeções Intralesionais/normas , Antimoniato de Meglumina
7.
Z Rheumatol ; 74(9): 764-73, 2015 Nov.
Artigo em Alemão | MEDLINE | ID: mdl-26431953

RESUMO

This article presents the spectrum of indications for the use of hyaluronic acid (HA) based on the recommendations of the European League Against Rheumatism (EULAR), the American College of Rheumatology (ACR), the Osteoarthritis Research Society International (OARSI), the International Institute for Health and Clinical Excellence (NICE) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) taking the reality of patient care in Europe into account.


Assuntos
Ácido Hialurônico/administração & dosagem , Ácido Hialurônico/normas , Guias de Prática Clínica como Assunto , Doenças Reumáticas/tratamento farmacológico , Reumatologia/normas , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/normas , Antirreumáticos/administração & dosagem , Antirreumáticos/normas , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos/normas , Europa (Continente) , Humanos , Injeções Intra-Articulares/métodos , Injeções Intra-Articulares/normas , Injeções Intralesionais/métodos , Injeções Intralesionais/normas , Doenças Reumáticas/diagnóstico , Estados Unidos , Viscossuplementos/administração & dosagem , Viscossuplementos/normas
8.
Am J Trop Med Hyg ; 75(2): 363-4, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16896149

RESUMO

Treating potentially rabies virus infected wounds requires the injection of rabies immunoglobulin into and around the wounds, followed by vaccination with an approved tissue culture rabies vaccine. A significant number of such bite wounds involves fingers where there is little space for expansion. Injecting immunoglobulin into such areas under pressure may induce a compartment syndrome caused by compromising circulation. We carried out a retrospective review and a prospective study of patients seen with digital bite injuries and found that it is a safe procedure if carried out with care by experienced staff.


Assuntos
Mordeduras e Picadas/terapia , Traumatismos dos Dedos/virologia , Imunoglobulinas/administração & dosagem , Raiva/prevenção & controle , Raiva/terapia , Adolescente , Adulto , Idoso , Animais , Criança , Pré-Escolar , Dedos , Humanos , Lactente , Injeções Intralesionais/métodos , Injeções Intralesionais/normas , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos Retrospectivos , Infecção dos Ferimentos/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA